Genetic polymorphisms of glutathione S-transferase M1 and bladder cancer risk: a meta-analysis of 26 studies

Abstract

Studies investigating the association between glutathione S-transferase M1 (GSTM1) polymorphism and bladder cancer risk report conflicting results. The objective of this study was to quantitatively summarize the evidence for such a relationship. We performed a systematic search of the National Library of Medline and Embase databases. This meta-analysis included 26 case-control studies, which included 5029 bladder cancer cases and 6680 controls. The combined results based on all studies showed that the GSTM1 null genotype was associated with an increased risk of bladder cancer (OR=1.46, 95% confidence interval [CI]=1.35, 1.57). When stratifying for race, results were similar among Asians (OR=1.60, 95% CI=1.27, 2.01) and Caucasians (OR=1.44, 95% CI=1.33, 1.57) except Africans (OR=1.25, 95% CI=0.76, 2.06). When stratifying by the smoking, stage, grade, and histological type of bladder cancer, we found no statistical association. Our meta-analysis suggests that the GSTM1 null genotype is associated with a modest increase in the risk of bladder cancer.

Polymorphic Deletions of Glutathione S-Transferases M1, T1 and Bladder Cancer Risk in Algerian Population

“…This finding is consistent with combined results of 26 studies represented in the meta-analysis of Zhang et al [26], including 5029 bladder cancer cases and 6680 controls. Other more recent studies carried out in India and Pakistan have given the same result [16,27].…”

“…Other more recent studies carried out in India and Pakistan have given the same result [16,27]. Among all studied ethnic groups, the association between GSTM1 null genotype and risk of bladder cancer was observed in Asians and Caucasians [26]. Conversely, in Tunisian and Egyptian populations results suggested that this polymorphism had no effect on risk of bladder carcinogenesis [24,[28][29][30].…”

No Association Between the GSTM1 Null Genotype and Risk of Renal Cell Carcinoma: A Meta-analysis

“…The relationship between GSTM1 polymorphism and cancer risk has been investigated in various studies (Wang et al, 2010;Liu and Xu, 2012;Kumar et al, 2011;Zhang et al, 2011;Zhu et al, 2012). Previous studies suggested GSTM1 null genotype was associated with risks of laryngeal cancer, cervical cancer, hepatocellular carcinoma and gastric cancer, but a race-specific effect may exist in those associations and a more obvious association was found in Asians (Wang et al, 2010;Kumar et al, 2011;Zhang et al, 2011;Liu and Xu, 2012;Zhu et al, 2012). Many studies have reported on the effect of ethnic differences on genetic predisposition to human diseases.…”

Serum vitamin C and other biomarkers differ by genotype of phase 2 enzyme genes GSTM1 and GSTT1

“…Meta-analyses have indicated that deletion of either GSTM1 or GSTT1 is associated with a significant increased risk of coronary heart disease (5), asthma (6), breast cancer (7)(8)(9), colon cancer (10)(11)(12), bladder cancer (13,14), liver cancer (15), lung cancer (16,17), esophagus cancer (18), several forms of leukemia (19)(20)(21), and prostate cancer (22).…”